Key Molecule Identified for Difficult-to-Treat Heart Failure
Table of Contents
Researchers at the German Center for Cardiovascular Research (DZHK) have pinpointed a crucial molecule that could unlock new treatments for heart failure with preserved ejection fraction (obesity/” title=”Semaglutide: Promising Treatment for … with Preserved Ejection Fraction (HFpEF) and …”>HFPEF). This form of heart weakness, often linked to obesity and high blood pressure, has historically presented significant challenges in therapeutic development. The discovery offers a beacon of hope for millions affected by this condition.
Understanding HFPEF
Heart failure with preserved ejection fraction (HFPEF) affects an increasing number of individuals, particularly those with underlying conditions like obesity or hypertension. While other types of heart failure have established treatment options, HFPEF has remained a difficult-to-treat condition with limited targeted therapies.
The Role of NNT
A team led by Prof. Johannes Backs at Heidelberg University
